Eureka Therapeutics
Sep 04, 2019
Driving factors boosting the Hepatocellular Carcinoma Market
The present Hepatocellular Carcinoma market size is mainly dominated by the protein Kinase inhibitor i.e., Nexavar (Sorafenib) developed by Bayer is considered the first line of treatment. Followed by the second line of treatments and off label Chemotherapies. Opdivo, leading drug of Bristol-Myers Squibb approv...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
